Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 539

1.

Polygenic adaptation and convergent evolution on growth and cardiac genetic pathways in African and Asian rainforest hunter-gatherers.

Bergey CM, Lopez M, Harrison GF, Patin E, Cohen JA, Quintana-Murci L, Barreiro LB, Perry GH.

Proc Natl Acad Sci U S A. 2018 Nov 9. pii: 201812135. doi: 10.1073/pnas.1812135115. [Epub ahead of print]

PMID:
30413626
2.

Genetic findings in adolescent and adult-onset leukodystrophies with hypomyelinating features.

Macaron G, Samaan S, Cohen JA, Nadjar Y.

J Neurol Neurosurg Psychiatry. 2018 Nov 2. pii: jnnp-2018-319214. doi: 10.1136/jnnp-2018-319214. [Epub ahead of print] No abstract available.

PMID:
30389777
3.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204. [Epub ahead of print]

PMID:
30334474
4.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
5.

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers.

Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM.

Neurol Clin Pract. 2018 Aug;8(4):292-301. doi: 10.1212/CPJ.0000000000000487.

6.

Helping Children With Traumatic Reactions to Parental Suicide.

Cohen JA, Mannarino AP.

J Am Acad Child Adolesc Psychiatry. 2018 Aug;57(8):619. doi: 10.1016/j.jaac.2018.05.009.

PMID:
30071985
7.

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.

Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators.

Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884. [Epub ahead of print]

PMID:
30043658
8.

Integrating multiple sclerosis guidelines into practice.

Macaron G, Cohen JA.

Lancet Neurol. 2018 Aug;17(8):658-660. doi: 10.1016/S1474-4422(18)30248-5. Epub 2018 Jul 17. No abstract available.

PMID:
30033052
9.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis - Authors' reply.

Thompson AJ, Reingold SC, Cohen JA; International Panel on Diagnosis of Multiple Sclerosis.

Lancet Neurol. 2018 Jun;17(6):499-500. doi: 10.1016/S1474-4422(18)30168-6. No abstract available.

PMID:
29778360
10.

Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis.

Planchon SM, Lingas KT, Reese Koç J, Hooper BM, Maitra B, Fox RM, Imrey PB, Drake KM, Aldred MA, Lazarus HM, Cohen JA.

Mult Scler J Exp Transl Clin. 2018 Mar 26;4(1):2055217318765288. doi: 10.1177/2055217318765288. eCollection 2018 Jan-Mar.

11.

Neuromuscular diseases associated with Human Immunodeficiency Virus infection.

Prior DE, Song N, Cohen JA.

J Neurol Sci. 2018 Apr 15;387:27-36. doi: 10.1016/j.jns.2018.01.016. Epub 2018 Jan 31. Review.

PMID:
29571868
12.

Being in-between: A model of cultural identity negotiation for emerging adult immigrants.

Cohen JA, Kassan A.

J Couns Psychol. 2018 Mar;65(2):133-154. doi: 10.1037/cou0000265.

PMID:
29543472
13.

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.

Baldassari LE, Cohen JA.

EBioMedicine. 2018 Mar;29:5-6. doi: 10.1016/j.ebiom.2018.02.021. Epub 2018 Feb 23. No abstract available.

14.

Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Cohen JA, Hunter SF, Brown TR, Gudesblatt M, Thrower BW, Llorens L, Souza-Prien CJ, Ruby AE, Chernoff DN, Patni R.

Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716. [Epub ahead of print]

PMID:
29368539
15.
16.
17.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
18.

Adjunctive Therapies for Catheter Ablation of Non-Paroxysmal Atrial Fibrillation.

Cohen JA, Mansour M.

J Atr Fibrillation. 2016 Dec 31;9(4):1490. doi: 10.4022/jafib.1490. eCollection 2016 Dec. Review.

19.

Comorbidities in MS are associated with treatment intolerance and disability.

McDonnell GV, Cohen JA.

Neurology. 2017 Nov 28;89(22):2218-2219. doi: 10.1212/WNL.0000000000004699. Epub 2017 Nov 1. No abstract available.

PMID:
29093072
20.

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.

Havrdova E, Cohen JA, Horakova D, Kovarova I, Meluzinova E.

Ther Clin Risk Manag. 2017 Oct 16;13:1423-1437. doi: 10.2147/TCRM.S143509. eCollection 2017. Review.

21.

Early versus late Gamma Knife radiosurgery following transsphenoidal surgery for nonfunctioning pituitary macroadenomas: a multicenter matched-cohort study.

Pomeraniec IJ, Kano H, Xu Z, Nguyen B, Siddiqui ZA, Silva D, Sharma M, Radwan H, Cohen JA, Dallapiazza RF, Iorio-Morin C, Wolf A, Jane JA Jr, Grills IS, Mathieu D, Kondziolka D, Lee CC, Wu CC, Cifarelli CP, Chytka T, Barnett GH, Lunsford LD, Sheehan JP.

J Neurosurg. 2018 Sep;129(3):648-657. doi: 10.3171/2017.5.JNS163069. Epub 2017 Oct 27.

PMID:
29076785
22.

Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.

Mahajan KR, Ko JS, Tetzlaff MT, Hudgens CW, Billings SD, Cohen JA.

Mult Scler Relat Disord. 2017 Oct;17:12-14. doi: 10.1016/j.msard.2017.06.004. Epub 2017 Jun 22.

PMID:
29055440
23.

Cell-based therapeutic strategies for multiple sclerosis.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis.

Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Review.

24.

Clinical outcome measures for progressive MS trials.

Ontaneda D, Cohen JA, Amato MP.

Mult Scler. 2017 Oct;23(12):1627-1635. doi: 10.1177/1352458517729465. Review.

PMID:
29041863
25.

Clemastine fumarate for promotion of optic nerve remyelination.

Cohen JA, Tesar PJ.

Lancet. 2017 Dec 2;390(10111):2421-2422. doi: 10.1016/S0140-6736(17)32639-9. Epub 2017 Oct 10. No abstract available.

PMID:
29029894
26.

Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.

Conway DS, Hua LH, Cohen JA.

Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1. No abstract available.

27.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.

28.

A Pilot Study of Trauma-Focused Cognitive-Behavioral Therapy Delivered via Telehealth Technology.

Stewart RW, Orengo-Aguayo RE, Cohen JA, Mannarino AP, de Arellano MA.

Child Maltreat. 2017 Nov;22(4):324-333. doi: 10.1177/1077559517725403. Epub 2017 Sep 4.

PMID:
28868894
29.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

30.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

31.

Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.

Chaudhry BZ, Cohen JA, Conway DS.

Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4. Review.

32.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

33.

Trauma-Focused Cognitive Behavioral Therapy for Commercially Sexually Exploited Youth.

Cohen JA, Mannarino AP, Kinnish K.

J Child Adolesc Trauma. 2017 Jun;10(2):175-185. doi: 10.1007/s40653-015-0073-9. Epub 2015 Dec 28.

34.

Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.

Smith AL, Cohen JA, Hua LH.

Neurotherapeutics. 2017 Oct;14(4):952-960. doi: 10.1007/s13311-017-0548-5. Review.

35.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
36.

Top 50 most-cited articles on craniovertebral junction surgery.

Alan N, Cohen JA, Zhou J, Pease M, Kanter AS, Okonkwo DO, Hamilton DK.

J Craniovertebr Junction Spine. 2017 Jan-Mar;8(1):22-32. doi: 10.4103/0974-8237.199883.

37.

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):704-710. doi: 10.1177/1352458517690823. Epub 2017 Feb 16.

38.

Risk associated with perioperative red blood cell transfusion in cranial surgery.

Cohen JA, Alan N, Seicean A, Weil RJ.

Neurosurg Rev. 2017 Oct;40(4):633-642. doi: 10.1007/s10143-017-0819-y. Epub 2017 Feb 3.

PMID:
28154997
39.

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

Selmaj K, Barkhof F, Belova AN, Wolf C, van den Tweel ER, Oberyé JJ, Mulder R, Egging DF, Koper NP, Cohen JA; GATE study group.

Mult Scler. 2017 Dec;23(14):1909-1917. doi: 10.1177/1352458516688956. Epub 2017 Jan 16.

40.

Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project.

Dickerson E, Davenport MS, Syed F, Stuve O, Cohen JA, Rinker JR, Goldman MD, Segal BM, Foerster BR; Michigan Radiology Quality Collaborative.

J Am Coll Radiol. 2017 Mar;14(3):371-379.e1. doi: 10.1016/j.jacr.2016.09.037. Epub 2016 Dec 5.

PMID:
27932248
41.

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D.

Mult Scler Relat Disord. 2016 Nov;10:44-52. doi: 10.1016/j.msard.2016.08.002. Epub 2016 Aug 8.

PMID:
27919497
42.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA.

Lancet. 2017 Apr 1;389(10076):1357-1366. doi: 10.1016/S0140-6736(16)31320-4. Epub 2016 Nov 24. Review.

PMID:
27889191
43.

Safety of monoclonal antibodies for the treatment of multiple sclerosis.

McGinley MP, Moss BP, Cohen JA.

Expert Opin Drug Saf. 2017 Jan;16(1):89-100. Epub 2016 Oct 31. Review.

PMID:
27756172
44.

Transient and persistent conduction abnormalities following transcatheter aortic valve replacement with the Edwards-Sapien prosthesis: a comparison between antegrade vs. retrograde approaches.

Sager SJ, Damluji AA, Cohen JA, Shah S, O'Neill BP, Alfonso CE, Martinez CA, Myerburg RJ, Heldman AW, Cohen MG, Williams DB, Carrillo RG.

J Interv Card Electrophysiol. 2016 Nov;47(2):143-151. Epub 2016 May 28.

PMID:
27236653
45.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

46.

Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

Conway DS, Thompson NR, Cohen JA.

Mult Scler Relat Disord. 2016 Sep;9:129-34. doi: 10.1016/j.msard.2016.07.017. Epub 2016 Jul 27.

PMID:
27645360
47.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

48.

Considerations in the development of generic disease therapies for multiple sclerosis.

Hua LH, Cohen JA.

Neurol Clin Pract. 2016 Aug;6(4):369-376. Review.

49.

Gastric Outlet Obstruction due to Gastrointestinal Amyloidosis.

Cohen JA, An J, Brown AW, Spearman D, Paredes A.

J Gastrointest Surg. 2017 Mar;21(3):600-601. doi: 10.1007/s11605-016-3248-2. Epub 2016 Aug 19.

PMID:
27542374
50.

Trauma-focused cognitive behavioral therapy for children and families.

Cohen JA, Deblinger E, Mannarino AP.

Psychother Res. 2018 Jan;28(1):47-57. doi: 10.1080/10503307.2016.1208375. Epub 2016 Jul 22.

PMID:
27449400

Supplemental Content

Loading ...
Support Center